Designing a new drug for chronic pain

Designing a new drug for chronic pain

(Medical Xpress)—Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded £1.4 million to design a new drug for the treatment of chronic pain.

The project funded by the Medical Research Council (MRC), addresses the long-standing and urgent need for effective therapies for chronic pain which affects around 20% of adults in Europe and the US, and more than eight million adult patients in the UK alone. Medication currently available to treat the condition is effective in only around 40% of sufferers and even these patients often struggle to maintain the balance between adequate pain relief and the adverse effects of current therapies.

Targeting the glycine receptor

The research team is examining compounds which target the glycine receptor, one of the principal inhibitory neuronal receptors in the central nervous system and crucial in the sensation of chronic pain. Through medicinal chemistry, computational methods and experimental testing, scientists successfully identified novel compounds which could be used for the treatment of chronic pain without unwanted sedative effects.

Professor Martin Leuwer, from the University's Department of Molecular and Clinical Pharmacology in the Institute of Translational Medicine, said: "This is an exciting project that expands our drug discovery portfolio into a new therapeutic area with a huge unmet medical need.  Our collaborative team of medicinal chemists, molecular modellers and neurobiologists have made significant advances in this area and this funding provides us with the opportunity to drive the project forward towards an entirely new class of drug for the treatment of chronic pain conditions. 

"We're aiming to develop molecules that target the glycine receptor, into a drug that can be administered as a tablet. Our project concept has been shown to work but further improvements are required if we are to reach the goal of generating a drug which is safe, effective and orally viable. Our ultimate aim is to allow chronic pain patients to regain a dramatically improved quality of life."

He added: "In view of the huge numbers of patients worldwide whose lives are wrecked by chronic pain, the fact that current treatment options are clearly insufficient and the dramatic toll on economies caused by millions of lost working hours, our causal treatment option has the potential to have a tremendous beneficial impact on individuals and societies."

add to favorites email to friend print save as pdf

Related Stories

Naturally occurring protein has a role in chronic pain

Jun 12, 2012

Researchers in France and Sweden have discovered how one of the body's own proteins is involved in generating chronic pain in rats. The results, which also suggest therapeutic interventions to alleviate long-lasting pain, ...

Chronic pain gene identified

Sep 08, 2011

British researchers say they have identified the gene that controls chronic pain, opening the door to new drug therapies that block the chemical processes that cause chronic back pain, headaches or arthritis.

Drug-free treatments offer hope for older people in pain

Sep 10, 2007

Mind-body therapies, which focus on the interactions between the mind, body and behavior, and the ways in which emotional, mental, social and behavioral factors can affect health, may be of particular benefit to elderly chronic ...

Recommended for you

New pain relief targets discovered

6 hours ago

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

Building 'smart' cell-based therapies

7 hours ago

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other ...

Proper stem cell function requires hydrogen sulfide

10 hours ago

Stem cells in bone marrow need to produce hydrogen sulfide in order to properly multiply and form bone tissue, according to a new study from the Center for Craniofacial Molecular Biology at the Herman Ostrow School of Dentistry ...

User comments